In the medical phase 1 study.

Affimed Therapeutics reports extra results from AFM13 phase 1 study in R/R Hodgkin lymphoma Affimed Therapeutics AG announced today additional results from its stage 1 clinical trial of AFM13 since monotherapy for the treatment of patients with advanced relapsing/refractory Hodgkin lymphoma. In the medical phase 1 study, 28 heavily pretreated patients experiencing R/R Hodgkin lymphoma received infusions of AFM13 with increasing dosages in the range of 0.01 mg/kg up to 7 mg/kg . AFM13 was administered once weekly over four weeks in a lot of the patients. Primary endpoints were protection and tolerability. Secondary endpoints had been pharmacokinetics, pharmacodynamics and clinical efficacy. The info were shown by Max Topp, Professor of Medicine at the University of Wuerzburg, at the AACR Annual Achieving 2014, NORTH PARK, CA, USA, on April 8, 2014.

The benefits are designed to alert users to any unpaid medical bills within their name from hospitals, doctors or additional health providers.. Affinion Security Middle announces option of new features in its IdentitySecure service Affinion Security Middle, a leading provider of identification theft protection solutions, today announced the option of new features in its IdentitySecure program to help people detect and resolve one of the most damaging types of identity theft: medical identity theft. The consequences for this type of identity theft can be grave if personal health records containing inaccurate info are used by healthcare providers in providing treatment.